IL-22 is known to induce STAT3 activation, which has also been observed in non-small cell lung cancer and is furthermore associated with poor prognosis, thus being a plausible mechanism for the effects on tumor burden in the mouse model. This evidence concerns the gene IL22 and non-small cell lung carcinoma.